UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13D
Under the Securities Exchange Act of 1934
 
(Amendment No. 9)
 
Genomic Health, Inc
(Name of Issuer)
 
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
 
 
37244C101
  
 
(CUSIP Number)
  
 
Leo Kirby
667 Madison Avenue, 21st Floor
New York, NY  10065
(212) 339-5633
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
 
 
March 7, 2011
  
 
(Date of Event which Requires Filing of this Statement)
  

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.   ¨
 
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 
 
 
SCHEDULE 13D
 
CUSIP No.
    37244C101   
  
Page   2  of   8  Pages
 
1
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Julian C. Baker
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
 
(b) ¨
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
¨
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
41,250
8
SHARED VOTING POWER
7,571,783
9
SOLE DISPOSITIVE POWER
41,250
10
SHARED DISPOSITIVE POWER
7,571,783
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,613,033
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
¨
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
26.3%
14
TYPE OF REPORTING PERSON (See Instructions)
IN
 
 
Page 2 of 8 Pages
 
 
SCHEDULE 13D
 
CUSIP No.
   37244C101   
  
Page   3  of   8  Pages

1
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Felix J. Baker
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
 
(b) ¨
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
¨
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
7,571,783
9
SOLE DISPOSITIVE POWER
  0
10
SHARED DISPOSITIVE POWER
7,571,783
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,571,783
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
¨
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
26.2%
14
TYPE OF REPORTING PERSON (See Instructions)
IN

 
Page 3 of 8 Pages
 
 
This Amendment No. 9 to Schedule 13D is being filed by Julian C. Baker and Felix J. Baker (the “Reporting Persons”) to supplement the statements on Schedule 13D previously filed by them, as heretofore amended.  Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.
 
Item 5.
Interest in Securities of the Issuer.
 
Set forth below is the aggregate number of shares of Common Stock held, including shares that maybe acquired upon exercise of Options as of the date hereof by each of the following, together with the percentage of outstanding shares of Common Stock that such number represents based upon 28,857,463 shares outstanding, as reported on the company’s SEC Form 10Q filed on November 9, 2010. Such percentage figures are calculated on the basis that the Options owned by the Reporting Persons are deemed exercised for shares of Common Stock but other outstanding Options are not deemed exercised.
 
Name
  
Number of
Shares
    
Percent of Class
Outstanding
  
                 
Baker Bros. Investments, L.P.
     173,897       0.6 %
Baker Bros. Investments II, L.P.
     20,287       0.1 %
667, L.P.
     1,253,653       4.3 %
Baker Brothers Life Sciences, L.P.
     5,603,248       19.4 %
14159, L.P.
     152,640       0.5 %
FBB Associates
     173,897       0.6 %
Baker/Tisch Investments, L.P.
     194,161       0.7 %
Julian C. Baker
     41,250       0.1 %
 
  
 
    
 
  
Total
     7,613,033       26.3 %
 
By virtue of their ownership of entities that have the power to control the investment decisions of the limited partnerships listed in the table above, Julian C. Baker and Felix J. Baker may each be deemed to be beneficial owners of shares owned by such entities and may be deemed to have shared power to vote or direct the vote of and shared power to dispose or direct the disposition of such securities.  Julian C. Baker and Felix J. Baker are also the sole partners of FBB Associates, a general partnership, and as such may be deemed to be beneficial owners of shares owned by FBB Associates and may be deemed to have shared power to vote or direct the vote and dispose or direct the disposition of those shares.
 
Julian C. Baker is a Director of the Company.
 
The following transactions in Common Stock were effected by the entities noted below during the sixty days preceding the filing of this statement. None of the reporting Persons has effected any other transactions in Common Stock during this period.
 
 
Page 4 of 8 Pages
 
 
 
  
 
  
Number of
          
Name
  
Date
  
Shares
  
Transaction
  
Price / Share
  
                   
Baker Brothers Life Sciences, L.P.
  
3/4/11
     9359  
Purchase
     25.4961  
14159, L.P.
  
3/4/11
     258  
Purchase
     25.4961  
Baker Brothers Life Sciences, L.P.
  
3/4/11
     41,041  
Purchase
     25.4435  
14159, L.P.
  
3/4/11
     1,133  
Purchase
     25.4435  
Baker Brothers Life Sciences, L.P.
  
3/7/11
     19,463  
Purchase
     25.4044  
14159, L.P.
  
3/7/11
     537  
Purchase
     25.4044  
Baker Brothers Life Sciences, L.P.
  
3/7/11
     34,592  
Purchase
     25.3915  
14159, L.P.
  
3/7/11
     955  
Purchase
     25.3915  
Baker Brothers Life Sciences, L.P.
  
3/7/11
     243,285  
Purchase
     24.9000  
14159, L.P.
  
3/7/11
     6,715  
Purchase
     24.9000  
Baker Brothers Life Sciences, L.P.
  
3/8/11
     1,826  
Purchase
     25.1296  
14159, L.P.
  
3/8/11
     50  
Purchase
     25.1296  
  
 
Page 5 of 8 Pages
 
 
Item 6.
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
 
Except as reported herein, neither of the Reporting Persons has any express contracts, arrangements or understandings with any other Reporting Person with respect to the securities of the Company.  Except as set forth in Item 7 below, none of the Reporting Persons has any contracts, arrangements, understandings or relationships with the Company.
 
Item 7.
Material to Be Filed as Exhibits.
 
Exhibit 1.
Agreement regarding the joint filing of this statement.
 
 
Page 6 of 8 Pages
 
 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
March 8, 2011

 
By:
/s/ Julian C. Baker
   
Julian C. Baker
   
 
By:
/s/ Felix J. Baker
   
Felix J. Baker

 
Page 7 of 8 Pages
 
 
EXHIBIT 1

AGREEMENT
 
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
 
March 8, 2011

 
By:
/s/ Julian C. Baker
   
Julian C. Baker
   
 
By:
/s/ Felix J. Baker
   
Felix J. Baker

 
Page 8 of 8 Pages